Evogene Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: data-quality checks not passed.
Under review: data-quality checks not passed. We'll show the comparison once resolved.
Evogene Ltd. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Evogene has little or no product revenue yet; it used $14m of cash in the twelve months. The diluted share count is up 38.2% on a year earlier, which dilutes existing holders. It passes 2 of our 3 financial-health checks.
Our model value for Evogene is under review, so past values are not shown until it is resolved.
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Evogene Ltd.'s trailing-twelve-month revenue fell 30.9% year on year, with a free-cash-flow margin of -353.9%.
Current signal Free cash flow diverging from earnings: TTM free cash flow grew 32.9% while net income grew 48.5%: a 16pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for EVGN from the sources we follow. See filings →
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
We value Evogene Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | ~$0.5 ~$1.2–$4.1 | Included, half weight |
| Cash-flow model (DCF) Free cash flow after stock pay, grown then faded to 2.5%, discounted at 8.5%. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Evogene Ltd. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Next results: November 19, 2026, before the open. Analysts expect revenue of $365000 and EPS of −$0.19 (range −$0.19 to −$0.19) for the quarter.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$1.10 | +33% | $1m | −63% |
| Next | −$0.60 | +46% | $3m | +81% |
The consensus EPS forecast for the current fiscal year is −35.3% on 90 days ago. In the last 30 days, 1 analyst raised Evogene Ltd.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$1.70 | −$0.80 |
| 60 days ago | −$1.70 | −$0.80 |
| 30 days ago | −$1.70 | −$0.80 |
| 7 days ago | −$1.70 | −$0.80 |
| Now | −$1.10 | −$0.60 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.27 | −$0.13 | +51.7% |
| Mar 2026 | −$0.27 | −$0.61 | −125.7% |
| Dec 2025 | −$0.26 | −$0.62 | −137.5% |
| Sept 2025 | −$0.41 | −$0.46 | −13.4% |
Adjusted EPS as companies report it, against the average analyst estimate.
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY15 Q4 | $11.1M |
| FY16 Q4 | $6.5M |
| FY17 Q4 | $3.4M |
| FY18 Q4 | $1.7M |
| FY19 Q4 | $753K |
| FY20 Q4 | $1M |
| FY21 Q4 | $930K |
| FY22 Q4 | $1.7M |
| FY23 Q4 | $3M |
| FY24 Q4 | $5.6M |
| FY25 Q4 | $3.9M |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY16 Q4 | -41.2% |
| FY17 Q4 | -48.3% |
| FY18 Q4 | -48.3% |
| FY19 Q4 | -56.9% |
| FY20 Q4 | 38.1% |
| FY21 Q4 | -10.6% |
| FY22 Q4 | 80.1% |
| FY23 Q4 | 78.0% |
| FY24 Q4 | 87.0% |
| FY25 Q4 | -30.9% |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY15 Q4 | -161.0% |
| FY16 Q4 | -322.5% |
| FY17 Q4 | -649.1% |
| FY18 Q4 | -1144.2% |
| FY19 Q4 | -2810.9% |
| FY20 Q4 | -2386.0% |
| FY21 Q4 | -3328.3% |
| FY22 Q4 | -1608.4% |
| FY23 Q4 | -745.5% |
| FY24 Q4 | -337.2% |
| FY25 Q4 | -364.2% |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY15 Q4 | -129.5% |
| FY16 Q4 | -191.1% |
| FY17 Q4 | -488.6% |
| FY18 Q4 | -889.2% |
| FY19 Q4 | -2465.6% |
| FY20 Q4 | -1941.9% |
| FY21 Q4 | -2748.7% |
| FY22 Q4 | -1483.5% |
| FY23 Q4 | -742.9% |
| FY24 Q4 | -364.5% |
| FY25 Q4 | -353.9% |
| Fiscal year | 2015 Dec 2015 | 2016 Dec 2016 | 2017 Dec 2017 | 2018 Dec 2018 | 2019 Dec 2019 | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | |||||||||||
| Revenue | 11 | 7 | 3 | 2 | 1 | 1 | 1 | 2 | 3 | 6 | 4 |
| Gross profit | 3 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | −0 |
| EBITDA | −17 | −20 | −22 | −20 | — | — | — | — | −22 | −18 | −14 |
| Operating income | −18 | −21 | −22 | −20 | −21 | −25 | −31 | −27 | −22 | −19 | −14 |
| Net income | −17 | −20 | −21 | −21 | −18 | −23 | −28 | −27 | −24 | −16 | −8 |
| Diluted EPS | — | — | — | — | — | −$8.30 | −$6.90 | −$6.44 | −$5.20 | −$2.90 | $1.08 |
| Growth (year on year) | |||||||||||
| Revenue | — | −41.2% | −48.3% | −48.3% | −56.9% | +38.1% | −10.6% | +80.1% | +78.0% | +87.0% | −30.9% |
| Margins | |||||||||||
| Gross margin | 25.8% | 13.8% | 15.9% | 16.9% | 55.6% | 44.8% | 17.5% | 45.7% | 50.0% | 57.3% | −6.3% |
| EBITDA margin | −152.4% | −313.3% | −640.0% | <−999% | — | — | — | — | −723.4% | −326.8% | −350.7% |
| Operating margin | −161.0% | −322.5% | −649.1% | <−999% | <−999% | <−999% | <−999% | <−999% | −745.5% | −337.2% | −364.2% |
| Net margin | −154.7% | −299.6% | −616.3% | <−999% | <−999% | <−999% | <−999% | <−999% | −800.8% | −295.6% | −220.2% |
| Free-cash-flow margin | −129.5% | −191.1% | −488.6% | −889.2% | <−999% | <−999% | <−999% | <−999% | −742.9% | −364.5% | −353.9% |
| Cash flow | |||||||||||
| Cash from operations | −12 | −12 | −16 | −15 | −18 | −20 | −25 | −24 | −22 | −20 | −14 |
| Capital spending | 2 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Free cash flow | −14 | −13 | −17 | −16 | −19 | −20 | −26 | −25 | −22 | −20 | −14 |
| Stock-based pay | 4 | 3 | 2 | 2 | 2 | 4 | 3 | 1 | 1 | 1 | 1 |
| Free cash flow after stock pay | −19 | −15 | −19 | −17 | −20 | −24 | −28 | −26 | −23 | −22 | −14 |
| Balance sheet | |||||||||||
| Cash | 10 | 3 | 3 | 6 | 35 | 46 | 32 | 29 | 21 | 15 | 13 |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative = net cash) | −10 | −3 | −3 | −6 | −35 | −46 | −32 | −29 | −21 | −15 | −13 |
| Diluted shares | 3m | 3m | 3m | 3m | 3m | 3m | 4m | 4m | 5m | 6m | 8m |
| Last 12 months unless stated | EVGN | DBVT | DYAI | ALGS | CAMP | CRIS | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $4m | $4m | $4m | $4m | $4m | $4m | $55m |
| Revenue growth, last 12 months | −30.9% | −31.6% | −8.0% | 19.4% | 40.2% | −62.2% | 12.2% |
| Revenue growth, 3-year average | — | −11.6% | 3.4% | −5.5% | — | −25.0% | 13.7% |
| Revenue growth, latest quarter | — | −42.9% | −0.6% | −100.0% | 18.8% | −100.0% | 10.2% |
| Gross margin | −6.3% | — | 16.2% | — | — | — | 82.8% |
| Operating margin | −364.2% | <−999% | −195.1% | <−999% | <−999% | −203.2% | −191.1% |
| Operating margin, 3-year average | <−999% | <−999% | −257.9% | <−999% | — | −341.2% | −365.3% |
| Net margin | −220.2% | <−999% | −200.5% | <−999% | <−999% | −490.3% | −172.8% |
| Cash from operations / revenue | −350.4% | <−999% | −194.7% | <−999% | −678.2% | −709.0% | −168.8% |
| Free-cash-flow margin | −353.9% | <−999% | — | <−999% | −681.2% | −709.0% | −168.1% |
| Free-cash-flow margin, 3-year average | <−999% | <−999% | — | <−999% | — | −465.5% | −313.4% |
| Stock pay / revenue | 17.0% | 335.9% | 17.1% | 149.8% | 131.4% | 66.4% | 19.2% |
| Change in share count | 38.2% | 216.3% | 20.3% | 30.7% | — | 90.7% | 8.3% |
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| HRT Financial LP | $45,000 | 107K | 37.5% | New |
| Susquehanna International Group, LLP | $33,889 | 80K | 28.2% | New |
| Citadel Advisors LLC | $21,383 | 51K | 17.8% | New |
| Xtx Topco Ltd | $8,212 | 19K | 6.8% | ▲ 52.5% |
| UBS Group AG | $4,737 | 11K | 3.9% | ▲ 69.9% |
| Daytona Street Capital LLC | $4,651 | 9K | 3.9% | ▼ 3.5% |
| BNP Paribas Financial Markets | $1,242 | 3K | 1.0% | ▼ 69.0% |
| Morgan Stanley | $564 | 1K | 0.5% | ▼ 66.6% |
| Federation Des Caisses Desjardins Du Quebec | $220 | 1K | 0.2% | 0.0% |
| Osaic Holdings, Inc. | $44 | 0K | 0.0% | 0.0% |
| Shp Wealth Management | $29 | 0K | 0.0% | 0.0% |
| Sbi Securities Co., Ltd. | $27 | 0K | 0.0% | ▼ 13.9% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Evogene Ltd.'s complete shareholder register. Values are as reported by the filers .
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Recanati Leon Director | August 11, 2026 | Buy | 460,000 | $0.64 | $294,400 |
| Recanati Leon Director | August 4, 2026 | Buy | 800,000 | $0.50 | $400,000 |
| Tarcic Gabi Chief Development Officer | June 4, 2026 | Buy | 1,129 | $0.60 | $677 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
